fig2

COVID-19 and rare diseases: reflections and recommendations by the International Rare Diseases Research Consortium

Figure 2. Patient Advocacy Organizations reporting impacts of the COVID-19 pandemic on their organization. The PAOs reported that their members were negatively impacted by the pandemic as a result of decreased access to treatments, clinical trials, and access to diagnostic paths (A). In addition, PAOs reported challenges in operations resulting from increased demand for information/support, cancellation of fundraising events, and decreased participation and support for research activities (B). PAOs: Patient Advocacy Organizations.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/